E115: Benralizumab for EGPA - the MANDARA Study

Update: 2024-10-28

Description

Quick rundown of an important rheumatology RCT this week, discussing the IL-5 inhibitor benralizumab for the treatment of relapsing/refractory EGPA.

MANDARA Study: https://www.nejm.org/doi/full/10.1056/NEJMoa2311155

Comments

In Channel

E129: Long Term Routine Laboratory Monitoring in RA

2025-12-0415:17

E128: Nerandomilast for Autoimmune ILD (FIBRONEER-ILD)

2025-11-1219:03

E127: TNFs and All That CHF

2025-09-2221:46

E126: Risk Signals, JAKs, and SELECTIVE-ity

2025-09-0814:34

E125: Adrenal Insufficiency after Stopping Prednisone

2025-06-2917:52

e124: MTX vs Pred for Pulmonary Sarcoidosis: PREDMETH Study

2025-06-1214:18

E123: Upadacitinib for Giant Cell Arteritis: SELECT-GCA

2025-04-3018:13

E122: Guidelines for Maybe Diagnosing HLH

2025-04-1711:18

E121: Obinutuzumab in SLE-LN

2025-04-0218:14

E120: Real Life Use of PEXIVAS-Low

2025-03-0624:33

E119: Teclistamab for Rheumatology Writ Large

2025-02-1010:52

E118: The emerging risk of overdiagnosis in RA and PMR

2025-01-3116:02

E117: Inebilizumab for IgG4-RD (MITIGATE)

2024-12-0312:55

E116: A New Paradigm for PMR

2024-11-1109:29

E115: Benralizumab for EGPA - the MANDARA Study

2024-10-2809:52

E114: Target Trials and STAR-RA with Rishi Desai

2024-10-1431:15

E113: CAR-T is Coming to Rheumatology

2024-09-3014:04

E112: Gabapentin is Trash

2024-09-1206:07

E111: PEXIVAS Subsets with Mike Walsh & Mats Junek

2024-03-2539:27

E110: Rheum4Debate - Screening for RA-ILD with Joshua Solomon and Scott Matson

2024-03-1424:19

00:00

E115: Benralizumab for EGPA - the MANDARA Study

#box-pro-ellipsis-17653671962588{-webkit-line-clamp:2;}E115: Benralizumab for EGPA - the MANDARA Study

E115: Benralizumab for EGPA - the MANDARA Study

Michael Putman

E115: Benralizumab for EGPA - the MANDARA Study